Contemporary Management of MIBC and Beyond (2024): Expert Guidance for Urologists
Availability
No future session
Expires on Dec 16, 2027
Cost
$0.00
Credit Offered
1.5 AMA PRA Category 1 Credit Credits
1.5 Participation Credits

COMPLIMENTARY CME LIVE VIRTUAL COURSE!


Join the AUA for Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists, featuring a dynamic live webinar tailored specifically for Urologists. This FREE live virtual course will showcase an expert multidisciplinary panel ready to dive into an engaging discussion on the latest breakthroughs and strategies in MIBC management on December 16, 2024, 7-8:30 p.m. Eastern Time. Don t miss this chance to elevate your expertise in this critical field. Register today!


Acknowledgements

Support provided by an independent educational grant from:

  • Astellas and Pfizer, Inc.
  • Urologists

After participating in this CME activity, participants will be able to:

  1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy.
  2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes.
  3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma.
  4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management.
  5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes.

Faculty Disclosures

EDUCATION COUNCIL DISCLOSURE

Education Council Disclosures_June 2024.pdf

COI REVIEW WORK GROUP DISCLOSURES

COI Review Workgroup Disclosures_June 2024.pdf

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Welcome and Introductions

Pre-test

Segment 1: Treatment Approach

Segment 2: Neoadjuvant and Adjuvant Therapies

Segment 3: Checkpoint Inhibitors and Antibody Drug Conjugates

Segment 4: Clinical Trials and Emerging Treatments

Segment 5: Patient and Family Education Strategies

Post-test

Questions and Answers

Wrap-up

AUA ACCREDITATION INFORMATION

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditTM .

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification relevant financial relationships that result in of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.